Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Endocrinology
Testolactone reverses hypogonadotropic hypogonadism in obese men
November 24th, 2003
Treatment with the aromatase inhibitor testolactone reversed hypogonadotropic hypogonadism in obese men. According to a study from the United States, "Studies from this laboratory have shown that obese men have elevated serum estrogen levels and diminished levels of follicle-stimulating hormone (FSH) and free and total testosterone, all in proportion to their degree of obesity. The decreases in testosterone and FSH constitute a state of hypogonadotropic hypogonadism (HHG), and we have hypothesized that it results from feedback suppression of the pituitary by the elevated estrogen levels." "We tested this hypothesis by lowering the serum estrogens of...
Source: Obesity & Diabetes Week (2003-11-24)
|
